<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nature</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Nature</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0028-0836</issn>
        <issn pub-type="epub">1476-4687</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC4231481</article-id>
        <article-id pub-id-type="pmcid-ver">PMC4231481.1</article-id>
        <article-id pub-id-type="pmcaid">4231481</article-id>
        <article-id pub-id-type="pmcaiid">4231481</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS629713</article-id>
        <article-id pub-id-type="pmid">25079552</article-id>
        <article-id pub-id-type="doi">10.1038/nature13385</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS629713</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA629713</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <collab>The Cancer Genome Atlas Research Network</collab>
          </contrib>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>09</day>
          <month>7</month>
          <year>2014</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>31</day>
          <month>7</month>
          <year>2014</year>
        </pub-date>
        <volume>511</volume>
        <issue>7511</issue>
        <issue-id pub-id-type="pmc-issue-id">245217</issue-id>
        <fpage>543</fpage>
        <lpage>550</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>20</day>
              <month>09</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>14</day>
              <month>11</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>14</day>
              <month>11</month>
              <year>2014</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-05-01 16:25:15.803">
              <day>01</day>
              <month>05</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© 2014 Macmillan Publishers Limited. All rights reserved</copyright-statement>
          <copyright-year>2014</copyright-year>
          <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
            <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported licence. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">http://creativecommons.org/licenses/by-nc-sa/3.0</ext-link></license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms629713.pdf"/>
        <abstract>
          <p id="P1">Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including <italic toggle="yes">RIT1</italic> activating mutations and newly described loss-of-function <italic toggle="yes">MGA</italic> mutations which are mutually exclusive with focal <italic toggle="yes">MYC</italic> amplification. <italic toggle="yes">EGFR</italic> mutations were more frequent in female patients, whereas mutations in <italic toggle="yes">RBM10</italic> were more common in males. Aberrations in <italic toggle="yes">NF1</italic>, <italic toggle="yes">MET</italic>, <italic toggle="yes">ERBB2</italic> and <italic toggle="yes">RIT1</italic> occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in <italic toggle="yes">MET</italic> mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <p id="P2">Lung cancer is the most common cause of global cancer-related mortality, leading to over a million deaths each year and adenocarcinoma is its most common histological type. Smoking is the major cause of lung adenocarcinoma but, as smoking rates decrease, proportionally more cases occur in never-smokers (defined as less than 100 cigarettes in a life-time). Recently, molecularly targeted therapies have dramatically improved treatment for patients whose tumours harbour somatically activated oncogenessuch as mutant <italic toggle="yes">EGFR</italic><sup><xref rid="R1" ref-type="bibr">1</xref></sup> or translocated <italic toggle="yes">ALK, RET,</italic> or<italic toggle="yes">ROS1</italic> (refs <xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R4" ref-type="bibr">4</xref>). Mutant <italic toggle="yes">BRAF</italic> and <italic toggle="yes">ERBB2</italic> (ref. <xref rid="R5" ref-type="bibr">5</xref>) are also investigational targets. However, mostlung adenocarcinomas either lack an identifiable driver oncogene, or harbour mutations in <italic toggle="yes">KRAS</italic> and are therefore still treated with conventional chemotherapy. Tumour suppressor gene abnormalities, such as those in <italic toggle="yes">TP53</italic> (ref. <xref rid="R6" ref-type="bibr">6</xref>)<italic toggle="yes">, STK11</italic> (ref. <xref rid="R7" ref-type="bibr">7</xref>), <italic toggle="yes">CDKN2A</italic><sup><xref rid="R8" ref-type="bibr">8</xref></sup>, <italic toggle="yes">KEAP1</italic> (ref. <xref rid="R9" ref-type="bibr">9</xref>), and <italic toggle="yes">SMARCA4</italic> (ref. <xref rid="R10" ref-type="bibr">10</xref>) are also common but are not currently clinically actionable. Finally, lung adenocarcinoma shows high rates of somatic mutation and genomic rearrangement, challenging identification of all but the most frequent driver gene alterations because of a large burden of passenger events per tumour genome<sup><xref rid="R11" ref-type="bibr">11</xref>–<xref rid="R13" ref-type="bibr">13</xref></sup>. Our efforts focused on comprehensive, multiplatform analysis of lung adenocarcinoma, with attention towards pathobiology and clinically actionable events.</p>
      <sec id="S1">
        <title>Clinical samples and histopathologic data</title>
        <p id="P3">We analysed tumour and matched normal material from 230 previously untreated lung adenocarcinoma patients who provided informed consent (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref>). All major histologic types of lung adenocarcinoma were represented: 5% lepidic, 33% acinar, 9% papillary, 14% micropapillary, 25% solid, 4% invasive mucinous, 0.4% colloid and 8% unclassifiable adenocarcinoma (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 1</xref>)<sup><xref rid="R14" ref-type="bibr">14</xref></sup>. Median follow-up was 19 months, and 163 patients were alive at the time of last follow-up. Eighty-one percent of patients reported pastor present smoking. <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref> summarizes demographics. DNA, RNA and protein were extracted from specimens and quality-control assessments were performed as described previously<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref> summarizes molecular estimates of tumour cellularity<sup><xref rid="R16" ref-type="bibr">16</xref></sup>.</p>
      </sec>
      <sec id="S2">
        <title>Somatically acquired DNA alterations</title>
        <p id="P4">We performed whole-exome sequencing (WES) on tumour and germ-line DNA, with a mean coverage of 97.6× and 95.8×, respectively, as performed previously<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. The mean somatic mutation rate across the TCGA cohort was 8.87 mutations per megabase (Mb) of DNA (range: 0.5–48, median: 5.78). The non-synonymous mutation rate was 6.86 per Mb. MutSig2CV<sup><xref rid="R18" ref-type="bibr">18</xref></sup> identified significantly mutated genes among our 230 cases along with 182 similarly-sequenced, previously reported lung adenocarcinomas<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. Analysis of these 412 tumour/normal pairs highlighted 18 statistically significant mutated genes (<xref rid="F1" ref-type="fig">Fig. 1 a</xref> shows co-mutation plot of TCGA samples (<italic toggle="yes">n</italic> =230), <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref> shows co-mutation plot of all samples used in the statistical analysis (<italic toggle="yes">n</italic> =412) and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 4</xref> contains complete MutSig2CV results, which also appear on the TCGA Data Portal along with many associated data files (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/luad_2014/">https://tcga-data.nci.nih.gov/docs/publications/luad_2014/</ext-link>). <italic toggle="yes">TP53</italic> was commonly mutated (46%). Mutations in <italic toggle="yes">KRAS</italic> (33%) were mutually exclusive with those in <italic toggle="yes">EGFR</italic> (14%). <italic toggle="yes">BRAF</italic> was also commonly mutated (10%), as were <italic toggle="yes">PIK3CA</italic> (7%), <italic toggle="yes">MET</italic> (7%) and the small GTPase gene, <italic toggle="yes">RIT1</italic> (2%). Mutations in tumour suppressor genes including <italic toggle="yes">STK11</italic> (17%), <italic toggle="yes">KEAP1</italic> (17%), <italic toggle="yes">NF1</italic> (11%), <italic toggle="yes">RB1</italic> (4%) and <italic toggle="yes">CDKN2A</italic> (4%) were observed. Mutations in chromatin modifying genes <italic toggle="yes">SETD2</italic>(9%), <italic toggle="yes">ARID1A</italic>(7%) and <italic toggle="yes">SMARCA4</italic> (6%) and the RNA splicing genes <italic toggle="yes">RBM10</italic> (8%) and <italic toggle="yes">U2AF1</italic> (3%) were also common. Recurrent mutations in the <italic toggle="yes">MGA</italic> gene (which encodes a Max-interacting protein on the MYC pathway<sup><xref rid="R19" ref-type="bibr">19</xref></sup>) occurred in 8% of samples. Loss-of-function (frameshift and nonsense) mutations in <italic toggle="yes">MGA</italic> were mutually exclusive with focal <italic toggle="yes">MYC</italic> amplification (Fisher’s exact test <italic toggle="yes">P</italic> =0.04), suggesting a hitherto unappreciated potential mechanism of MYC pathway activation. Coding single nucleotide variants and indel variants were verified by resequencing at a rate of 99% and 100%, respectively (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3a</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>). Tumour purity was not associated with the presence of false negatives identified in the validation data (<italic toggle="yes">P</italic> =0.31; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3b</xref>).</p>
        <p id="P5">Past or present smoking associated with cytosine to adenine (C &gt;A) nucleotide transversions as previously described both in individual genes and genome-wide<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup>. C &gt;A nucleotide transversion fraction showed two peaks; this fraction correlated with total mutation count (<italic toggle="yes">R</italic><sup>2</sup> =0.30) and inversely correlated with cytosine to thymine (C &gt;T) transition frequency (<italic toggle="yes">R</italic><sup>2</sup> =0.75) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4</xref>). We classified each sample (<xref rid="SD1" ref-type="supplementary-material">Supplementary Methods</xref>) into one of two groups named transversion-high (TH, <italic toggle="yes">n</italic> =269), and transversion-low (TL, <italic toggle="yes">n</italic> =144). The transversion-high group was strongly associated with past or present smoking (<italic toggle="yes">P</italic> &lt; 2.2 ×10<sup>−16</sup>), consistent with previous reports<sup><xref rid="R13" ref-type="bibr">13</xref></sup>. The transversion-high and transversion-low patient cohorts harboured different gene mutations. Whereas <italic toggle="yes">KRAS</italic> mutations were significantly enriched in the transversion-highcohort (<italic toggle="yes">P</italic>=2.1×10<sup>−13</sup>), <italic toggle="yes">EGFR</italic> mutations were significantly enriched in the transversion-low group (<italic toggle="yes">P</italic> =3.3 ×10<sup>−6</sup>). <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">RB1</italic> mutations were likewise enriched in transversion-low tumours (<italic toggle="yes">P</italic> &lt;0.05). Additionally, the transversion-low tumours were specifically enriched for in-frame insertions in <italic toggle="yes">EGFR</italic> and <italic toggle="yes">ERBB2</italic> (ref. <xref rid="R5" ref-type="bibr">5</xref>) and for frameshift indels in <italic toggle="yes">RB1</italic> (<xref rid="F1" ref-type="fig">Fig. 1b</xref>). <italic toggle="yes">RB1</italic> is commonly mutated in small-cell lung carcinoma (SCLC). We found <italic toggle="yes">RB1</italic> mutations in transversion-low adenocarcinomas were enriched for frameshift indels versus single nucleotide substitutions compared to SCLC (<italic toggle="yes">P</italic> &lt;0.05)<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> suggesting a mutational mechanism in transversion-low adenocarcinoma that is probably distinct from smoking in SCLC.</p>
        <p id="P6">Gender is correlated with mutation patterns in lung adenocarcinoma<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. Only a fraction of significantly mutated genes from the complete set reported in this study (<xref rid="F1" ref-type="fig">Fig. 1a</xref>) were enriched in men or women (<xref rid="F1" ref-type="fig">Fig. 1c</xref>). <italic toggle="yes">EGFR</italic> mutations were enriched in tumours from the female cohort (<italic toggle="yes">P</italic> =0.03) whereas loss-of-function mutations within <italic toggle="yes">RBM10</italic>, an RNA-binding protein located on the X chromosome<sup><xref rid="R23" ref-type="bibr">23</xref></sup> were enriched in tumours from men (<italic toggle="yes">P</italic> =0.002). When examining the transversion-high group, 16 out of 21 <italic toggle="yes">RBM10</italic> mutations were observed in males (<italic toggle="yes">P</italic> =0.003, Fisher’s exact test).</p>
        <p id="P7">Somatic copy number alterations were very similar to those previously reported for lung adenocarcinoma<sup><xref rid="R24" ref-type="bibr">24</xref></sup> (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 5</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>). Significant amplifications included <italic toggle="yes">NKX2-1, TERT, MDM2, KRAS, EGFR, MET, CCNE1, CCND1, TERC</italic> and <italic toggle="yes">MECOM</italic> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>), as previously described<sup><xref rid="R24" ref-type="bibr">24</xref></sup>, 8q24 near <italic toggle="yes">MYC,</italic> and a novel peak containing <italic toggle="yes">CCND3</italic> (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>). The <italic toggle="yes">CDKN2A</italic> locus was the most significant deletion (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>). <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 7</xref> summarizes molecular and clinical characteristics by sample. Low-pass whole-genome sequencing on a subset (<italic toggle="yes">n</italic> =93) of the samples revealed an average of 36 gene–gene and gene–inter-gene rearrangements per tumour. Chromothripsis<sup><xref rid="R25" ref-type="bibr">25</xref></sup> occurred in six of the 93 samples (6%) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 6</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 8</xref>). Low-pass whole genome sequencing-detected rearrangements appear in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 9</xref>.</p>
      </sec>
      <sec id="S3">
        <title>Description of aberrant RNA transcripts</title>
        <p id="P8">Gene fusions, splice site mutations or mutations in genes encoding splicing factors promote or sustain the malignant phenotype by generating aberrant RNA transcripts. Combining DNA with mRNA sequencing enabled us to catalogue aberrant RNA transcripts and, in many cases, to identify the DNA-encoded mechanism for the aberration. Seventy-five per cent of somatic mutations identified by WES were present in the RNA transcriptome when the locus in question was expressed (minimum 5×) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7a</xref>) similar to prior analyses<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. Previously identified fusions involving <italic toggle="yes">ALK</italic> (3/230 cases), <italic toggle="yes">ROS1</italic> (4/230) and <italic toggle="yes">RET</italic> (2/230) (<xref rid="F2" ref-type="fig">Fig. 2a</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 10</xref>), all occurred in transversion-low tumours (<italic toggle="yes">P</italic> =1.85 × 10<sup>−4</sup>, Fisher’s exact test).</p>
        <p id="P9"><italic toggle="yes">MET</italic> activation can occur by exon 14 skipping, which results in a stabilized protein<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. Ten tumours had somatic <italic toggle="yes">MET</italic> DNA alterations with <italic toggle="yes">MET</italic> exon 14 skipping in RNA. In nine of these samples, a 5′ or 3′ splice site mutation or deletion was identified<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. <italic toggle="yes">MET</italic> exon 14 skipping was also found in the setting of a <italic toggle="yes">MET</italic> Y1003* stop codon mutation (<xref rid="F2" ref-type="fig">Fig. 2b</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8a</xref>). The codon affected by the Y1003* mutation is predicted to disrupt multiple splicing enhancer sequences, but the mechanism of skipping remains unknown in this case.</p>
        <p id="P10">S34F mutations in <italic toggle="yes">U2AF1</italic> have recently been reported in lung adenocarcinoma<sup><xref rid="R12" ref-type="bibr">12</xref></sup> but their contribution to oncogenesis remains unknown. Eight samples harboured <italic toggle="yes">U2AF1</italic><sup>S34F</sup>. We identified 129 splicing events strongly associated with <italic toggle="yes">U2AF1</italic><sup>S34F</sup> mutation, consistent with the role of U2AF1 in 3′-splice site selection<sup><xref rid="R28" ref-type="bibr">28</xref></sup>. Cassette exons and alternative 3′ splice sites were most commonly affected (<xref rid="F2" ref-type="fig">Fig. 2c</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 11</xref>)<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. Among these events, alternative splicing of the <italic toggle="yes">CTNNB1</italic> protooncogene was strongly associated with <italic toggle="yes">U2AF1</italic> mutations (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8b</xref>). Thus, concurrent analysis of DNA and RNA enabled delineation of both <italic toggle="yes">cis</italic> and <italic toggle="yes">trans</italic> mechanisms governing RNA processing in lung adenocarcinoma.</p>
      </sec>
      <sec id="S4">
        <title>Candidate driver genes</title>
        <p id="P11">The receptor tyrosine kinase (RTK)/RAS/RAF pathway is frequently mutated in lung adenocarcinoma. Striking therapeutic responses are often achieved when mutant pathway components are successfully inhibited. Sixty-two percent (143/230) of tumours harboured known activating mutations in known driver oncogenes, as defined by others<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. Cancer-associated mutations in <italic toggle="yes">KRAS</italic> (32%, <italic toggle="yes">n</italic> =74), <italic toggle="yes">EGFR</italic> (11%, <italic toggle="yes">n</italic> =26) and <italic toggle="yes">BRAF</italic> (7%, <italic toggle="yes">n</italic> =16) were common. Additional, previously uncharacterized <italic toggle="yes">KRAS</italic>, <italic toggle="yes">EGFR</italic> and <italic toggle="yes">BRAF</italic> mutations were observed, but were not classified as driver oncogenes for the purposes of our analyses (see <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 9a</xref> for depiction of all mutations of known and unknown significance); explaining the differing mutation frequencies in each gene between this analysis and the overall mutational analysis described above. We also identified known activating <italic toggle="yes">ERBB2</italic> in-frame insertion and point mutations (<italic toggle="yes">n</italic> =5)<sup><xref rid="R6" ref-type="bibr">6</xref></sup>, as well as mutations in <italic toggle="yes">MAP2K1</italic> (<italic toggle="yes">n</italic> =2), <italic toggle="yes">NRAS</italic> and <italic toggle="yes">HRAS</italic> (<italic toggle="yes">n</italic> =1 each). RNA sequencing revealed the aforementioned <italic toggle="yes">MET</italic> exon 14 skipping (<italic toggle="yes">n</italic> =10) and fusions involving <italic toggle="yes">ROS1</italic> (<italic toggle="yes">n</italic> =4), <italic toggle="yes">ALK</italic> (<italic toggle="yes">n</italic> =3) and <italic toggle="yes">RET</italic> (<italic toggle="yes">n</italic> =2). We considered these tumours collectively as oncogene-positive, as they harboured a known activating RTK/RAS/ RAF pathway somatic event. DNA amplification events were not considered to be driver events before the comparisons described below.</p>
        <p id="P12">We sought to nominate previously unrecognized genomic events that might activate this critical pathway in the 38% of samples without a RTK/RAS/RAF oncogene mutation. Tumour cellularity did not differ between oncogene-negative and oncogene-positive samples (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 9b</xref>). Analysis of copy number alterations using GISTIC<sup><xref rid="R31" ref-type="bibr">31</xref></sup> identified unique focal <italic toggle="yes">ERBB2</italic> and <italic toggle="yes">MET</italic> amplifications in the oncogene-negative subset (<xref rid="F3" ref-type="fig">Fig. 3a</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>); amplifications in other wild-type proto-oncogenes, including <italic toggle="yes">KRAS</italic> and <italic toggle="yes">EGFR,</italic> were not significantly different between the two groups.</p>
        <p id="P13">We next analysed WES data independently in the oncogene-negative and oncogene-positive subsets. We found that <italic toggle="yes">TP53</italic>, <italic toggle="yes">KEAP1</italic>, <italic toggle="yes">NF1</italic> and <italic toggle="yes">RIT1</italic> mutations were significantly enriched in oncogene-negative tumours (<italic toggle="yes">P</italic> &lt;0.01; <xref rid="F3" ref-type="fig">Fig. 3b</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 12</xref>). <italic toggle="yes">NF1</italic> mutations have previously been reported in lung adenocarcinoma<sup><xref rid="R11" ref-type="bibr">11</xref></sup>, but this is the first study, to our knowledge, capable of identifying all classes of loss-of-function <italic toggle="yes">NF1</italic> defects and to statistically demonstrate that <italic toggle="yes">NF1</italic> mutations, as well as <italic toggle="yes">KEAP1</italic> and <italic toggle="yes">TP53</italic> mutations are enriched in the oncogene-negative subset of lung adenocarcinomas (<xref rid="F3" ref-type="fig">Fig. 3c</xref>). All <italic toggle="yes">RIT1</italic> mutations occurred in the oncogene-negative subset and clustered around residue Q79 (homologous to Q61 in the switch II region of <italic toggle="yes">RAS</italic> genes). These mutations transform NIH3T3 cells and activate MAPK and PI(3)K signalling<sup><xref rid="R32" ref-type="bibr">32</xref></sup>, supporting a driver role for mutant <italic toggle="yes">RIT1</italic> in 2% of lung adenocarcinomas. This analysis increases the rate at which putative somatic lung adenocarcinoma driver events can be identified within the RTK/RAS/RAF pathway to 76% (<xref rid="F3" ref-type="fig">Fig. 3d</xref>).</p>
      </sec>
      <sec id="S5">
        <title>Recurrent alterations in key pathways</title>
        <p id="P14">Recurrent aberrations in multiple key pathways and processes characterize lung adenocarcinoma (<xref rid="F4" ref-type="fig">Fig. 4a</xref>). Among these were RTK/RAS/ RAF pathway activation (76% of cases), PI(3)K-mTOR pathway activation (25%), p53 pathway alteration (63%), alteration of cell cycle regulators (64%, <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 10</xref>), alteration of oxidative stress pathways (22%, <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 11</xref>), and mutation of various chromatin and RNA splicing factors (49%).</p>
        <p id="P15">We then examined the phenotypic sequelae of some key genomic events in the tumours in which they occurred. Reverse-phase protein arrays provided proteomic and phosphoproteomic phenotypic evidence of pathway activity. Antibodies on this platform are listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 13</xref>. This analysis suggested that DNA sequencing did not identify all samples with phosphoprotein evidence of activation of a given signalling pathway. For example, whereas <italic toggle="yes">KRAS</italic>-mutant lung adenocarcinomas had higher levels of phosphorylated MAPK than <italic toggle="yes">KRAS</italic> wild-type tumours had on average, many <italic toggle="yes">KRAS</italic> wild-type tumours displayed significant MAPK pathway activation (<xref rid="F4" ref-type="fig">Fig. 4b</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 10</xref>). The multiple mechanisms by which lung adenocarcinomas achieve MAPK activation suggest additional, still undetected RTK/RAS/ RAF pathway alterations. Similarly, we found significant activation of mTOR and its effectors (p70S6kinase, S6, 4E-BP1) in a substantial fraction of the tumours (<xref rid="F4" ref-type="fig">Fig. 4c</xref>). Analysis of mutations in <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">STK11</italic>, STK11 protein levels, and AMPK and AKT phosphorylation<sup><xref rid="R33" ref-type="bibr">33</xref></sup> led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either <italic toggle="yes">STK11</italic>-inactivating mutation or combined low STK11 expression and low AMPK activation and (3) tumours showing high mTOR activity accompanied by either phosphorylated AKT activation, <italic toggle="yes">PIK3CA</italic> mutation, or both. As with MAPK, many tumours lack an obvious underlying genomic alteration to explain their apparent mTOR activation.</p>
      </sec>
      <sec id="S6">
        <title>Molecular subtypes of lung adenocarcinoma</title>
        <p id="P16">Broad transcriptional and epigenetic profiling can reveal downstream consequences of driver mutations, provide clinically relevant classification and offer insight into tumours lacking clear drivers. Prior unsupervised analyses of lung adenocarcinoma gene expression have used varying nomenclature for transcriptional subtypes of the disease<sup><xref rid="R34" ref-type="bibr">34</xref>–<xref rid="R37" ref-type="bibr">37</xref></sup>. To coordinate naming of the transcriptional subtypes with the histopathological<sup><xref rid="R38" ref-type="bibr">38</xref></sup>, anatomic and mutational classifications of lung adenocarcinoma, we propose an updated nomenclature: the terminal respiratory unit (TRU, formerly bronchioid), the proximal-inflammatory (PI, formerly squamoid), and the proximal-proliferative (PP, formerly magnoid)<sup><xref rid="R39" ref-type="bibr">39</xref></sup> transcriptional subtypes (<xref rid="F5" ref-type="fig">Fig. 5a</xref>). Previously reported associations of expression signatures with pathways and clinical outcomes<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup> were observed (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7b</xref>) and integration with multi-analyte data revealed statistically significant genomic alterations associated with these transcriptional subtypes. The PP subtype was enriched for mutation of <italic toggle="yes">KRAS</italic>, along with inactivation of the <italic toggle="yes">STK11</italic> tumour suppressor gene by chromosomal loss, inactivating mutation, and reduced gene expression. In contrast, the PI subtype was characterized by solid histopathology and co-mutation of <italic toggle="yes">NF1</italic> and <italic toggle="yes">TP53</italic>. Finally, the TRU subtype harboured the majority of the <italic toggle="yes">EGFR</italic>-mutated tumours as well as the kinase fusion expressing tumours. TRU subtype membership was prognostically favourable, as seen previously<sup><xref rid="R34" ref-type="bibr">34</xref></sup> (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7c</xref>). Finally, the subtypes exhibited different mutation rates, transition frequencies, genomic ploidy profiles, patterns of large-scale aberration, and differed in their association with smoking history (<xref rid="F5" ref-type="fig">Fig. 5a</xref>). Unsupervised clustering of miRNA sequencing-derived or reverse phase protein array (RPPA)-derived data also revealed significant heterogeneity, partially overlapping with the mRNA-based subtypes, as demonstrated in <xref rid="SD2" ref-type="supplementary-material">Supplementary Figs 12 and 13</xref>.</p>
        <p id="P17">Mutations in chromatin-modifying genes (for example, <italic toggle="yes">SMARCA4</italic>, <italic toggle="yes">ARID1A</italic> and <italic toggle="yes">SETD2</italic>) suggest a major role for chromatin maintenance in lung adenocarcinoma. To examine chromatin states in an unbiased manner, we selected the most variable DNA methylation-specific probes in CpG island promoter regions and clustered them by methylation intensity (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 14</xref>). This analysis divided samples into two distinct subsets: a significantly altered CpG island methylator phenotype-high (CIMP-H(igh)) cluster and a more normal-like CIMP-L(ow) group, with a third set of samples occupying an intermediate level of methylation at CIMP sites (<xref rid="F5" ref-type="fig">Fig. 5b</xref>). Our results confirm a prior report<sup><xref rid="R40" ref-type="bibr">40</xref></sup> and provide additional insights into this epigenetic program. CIMP-H tumours often showed DNA hypermethylation of several key genes: <italic toggle="yes">CDKN2A, GATA2, GATA4, GATA5, HIC1, HOXA9, HOXD13, RASSF1</italic>, <italic toggle="yes">SFRP1, SOX17</italic> and <italic toggle="yes">WIF1</italic> among others (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 14</xref>). WNT pathway genes are significantly over-represented in this list (<italic toggle="yes">P</italic> value =0.0015) suggesting that this is a key pathway with an important driving role within this subtype. <italic toggle="yes">MYC</italic> overexpression was significantly associated with the CIMP-H phenotype as well (<italic toggle="yes">P</italic> =0.003).</p>
        <p id="P18">Although we did not find significant correlations between global DNA methylation patterns and individual mutations in chromatin remodelling genes, there was an intriguing association between <italic toggle="yes">SETD2</italic> mutation and <italic toggle="yes">CDKN2A</italic> methylation. Tumours with low <italic toggle="yes">CDKN2A</italic> expression due to methylation (rather than due to mutation or deletion) had lower ploidy, fewer overall mutations (<xref rid="F5" ref-type="fig">Fig. 5c</xref>) and were significantly enriched for <italic toggle="yes">SETD2</italic> mutation, suggesting an important role for this chromatin-modifying gene in the development of certain tumours.</p>
        <p id="P19">Integrative clustering<sup><xref rid="R41" ref-type="bibr">41</xref></sup> of copy number, DNA methylation and mRNA expression data found six clusters (<xref rid="F5" ref-type="fig">Fig. 5c</xref>). Tumour ploidy and mutation rate are higher in clusters 1–3 than in clusters 4–6. Clusters 1–3 frequently harbour <italic toggle="yes">TP53</italic> mutations and are enriched for the two proximal transcriptional subtypes. Fisher’s combined probability tests revealed significant copy number associated gene expression changes on 3q in cluster one, 8q in cluster two, and chromosome 7 and 15q in cluster three (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 15</xref>). The low ploidy and low mutation rate clusters four and five contain many TRU samples, whereas tumours in cluster 6 have comparatively lower tumour cellularity, and few other distinguishing molecular features. Significant copy number-associated gene expression changes are observed on 6q in cluster four and 19p in cluster five. The CIMP-H tumours divided into a high ploidy, high mutation rate, proximal-inflammatory CIMP-H group (cluster 3) and a low ploidy, low mutation rate, TRU-associated CIMP-H group (cluster 4), suggesting that the CIMP phenotype in lung adenocarcinoma can occur in markedly different genomic and transcriptional contexts. Furthermore, cluster four is enriched for <italic toggle="yes">CDKN2A</italic> methylation and <italic toggle="yes">SETD2</italic> mutations, suggesting an interaction between somatic mutation of <italic toggle="yes">SETD2</italic>andderegulated chromatin maintenance in this subtype. Finally, cluster membership was significantly associated with mutations in <italic toggle="yes">TP53</italic>, <italic toggle="yes">EGFR</italic> and <italic toggle="yes">STK11</italic> (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 15</xref>, <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>).</p>
      </sec>
      <sec sec-type="conclusions" id="S7">
        <title>Conclusions</title>
        <p id="P20">We assessed the mutation profiles, structural rearrangements, copy number alterations, DNA methylation, mRNA, miRNA and protein expression of 230 lung adenocarcinomas. In recent years, the treatment of lung adenocarcinoma has been advanced by the development of multiple therapies targeted against alterations in the RTK/RAS/RAF pathway. We nominate amplifications in <italic toggle="yes">MET</italic> and <italic toggle="yes">ERBB2</italic> as well as mutations of <italic toggle="yes">NF1</italic> and <italic toggle="yes">RIT1</italic> as driver events specifically in otherwise oncogene-negative lung adenocarcinomas. This analysis increases the fraction of lung adenocarcinoma cases with somatic evidence of RTK/RAS/RAF activation from 62% to 76%. While all lung adenocarcinomas may activate this pathway by some mechanism, only a subset show tonic pathway activation at the protein level, suggesting both diversity between tumours with seemingly similar activating events and as yet undescribed mechanisms of pathway activation. Therefore, the current study expands the range of possible targetable alterations within the RTK/RAS/RAF pathway in general and suggests increased implementation of MET and ERBB2/HER2 inhibitors in particular. Our discovery of inactivating mutations of <italic toggle="yes">MGA</italic> further underscores the importance of the MYC pathway in lung adenocarcinoma.</p>
        <p id="P21">This study further implicates both chromatin modifications and splicing alterations in lung adenocarcinoma through the integration of DNA, transcriptome and methylome analysis. We identified alternative splicing due to both splicing factor mutations in <italic toggle="yes">trans</italic> and mutation of splice sites in <italic toggle="yes">cis</italic>, the latter leading to activation of the <italic toggle="yes">MET</italic> gene by exon 14 skipping. Cluster analysis separated tumours based on single-gene driver events as well as large-scale aberrations, emphasizing lung adenocarcinoma’s molecular heterogeneity and combinatorial alterations, including the identification of coincident <italic toggle="yes">SETD2</italic> mutations and <italic toggle="yes">CDKN2A</italic> methylation in a subset of CIMP-H tumours, providing evidence of a somatic event associated with a genome-wide methylation phenotype. These studies provide new knowledge by illuminating modes of genomic alteration, highlighting previously unappreciated altered genes, and enabling further refinement in sub-classification for the improved personalization of treatment for this deadly disease.</p>
      </sec>
      <sec id="S8">
        <title>METHODS SUMMARY</title>
        <p id="P22">All specimens were obtained from patients with appropriate consent from the relevant institutional review board. DNA and RNA were collected from samples using the Allprep kit (Qiagen). We used standard approaches for capture and sequencing of exomes from tumour DNA and normal DNA<sup><xref rid="R15" ref-type="bibr">15</xref></sup> and whole-genome shotgun sequencing. Significantly mutated genes were identified by comparing them with expectation models based on the exact measured rates of specific sequence lesions<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. GISTIC analysis of the circular-binary-segmented Affymetrix SNP 6.0 copy number data was used to identify recurrent amplification and deletion peaks<sup><xref rid="R31" ref-type="bibr">31</xref></sup>. Consensus clustering approaches were used to analyse mRNA, miRNA and methylation subtypes using previous approaches<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. The publication web page is (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/luad_2014/">https://tcga-data.nci.nih.gov/docs/publications/luad_2014/</ext-link>). Sequence files are in CGHub (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link>).</p>
      </sec>
      <sec sec-type="supplementary-material" id="S9">
        <title>Supplementary Material</title>
        <supplementary-material content-type="local-data" id="SD1" position="float" orientation="portrait">
          <label>Supllementary information 2</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS629713-supplement-Supllementary_information_2.xlsx" orientation="portrait" id="d36e1142" position="anchor"/>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="SD2" position="float" orientation="portrait">
          <label>Supplementary information 1</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHMS629713-supplement-Supplementary_information_1.pdf" orientation="portrait" id="d36e1146" position="anchor"/>
        </supplementary-material>
      </sec>
    </body>
    <back>
      <ack id="S10">
        <p>This study was supported by NIH grants: U24 CA126561, U24 CA126551, U24 CA126554, U24 CA126543, U24 CA126546, U24 CA137153, U24 CA126563, U24 CA126544, U24 CA143845, U24 CA143858, U24 CA144025, U24 CA143882, U24 CA143866, U24 CA143867, U24 CA143848, U24 CA143840, U24 CA143835, U24 CA143799, U24 CA143883, U24 CA143843, U54 HG003067, U54 HG003079 and U54 HG003273. We thank K. Guebert and L. Gaffney for assistance and C. Gunter for review.</p>
      </ack>
      <fn-group>
        <fn id="FN1">
          <label>1</label>
          <p>University of California San Francisco, San Francisco, California 94158, USA.</p>
        </fn>
        <fn id="FN2">
          <label>2</label>
          <p>The Eliand Edythe L. Broad Institute, Cambridge, Massachusetts 02142, USA.</p>
        </fn>
        <fn id="FN3">
          <label>3</label>
          <p>Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.</p>
        </fn>
        <fn id="FN4">
          <label>4</label>
          <p>Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.</p>
        </fn>
        <fn id="FN5">
          <label>5</label>
          <p>University of Michigan, Ann Arbor, Michigan 48109, USA.</p>
        </fn>
        <fn id="FN6">
          <label>6</label>
          <p>Johns Hopkins University, Baltimore, Maryland 21287, USA.</p>
        </fn>
        <fn id="FN7">
          <label>7</label>
          <p>Baylor College of Medicine, Houston, Texas 77030, USA.</p>
        </fn>
        <fn id="FN8">
          <label>8</label>
          <p>Washington University, St. Louis, Missouri 63108, USA.</p>
        </fn>
        <fn id="FN9">
          <label>9</label>
          <p>Harvard Medical School, Boston, Massachusetts 02115, USA.</p>
        </fn>
        <fn id="FN10">
          <label>10</label>
          <p>Massachusetts General Hospital, Boston, Massachusetts 02114, USA.</p>
        </fn>
        <fn id="FN11">
          <label>11</label>
          <p>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.</p>
        </fn>
        <fn id="FN12">
          <label>12</label>
          <p>University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.</p>
        </fn>
        <fn id="FN13">
          <label>13</label>
          <p>Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9, Canada.</p>
        </fn>
        <fn id="FN14">
          <label>14</label>
          <p>Brigham and Women’s Hospital Boston, Massachusetts 02115, USA.</p>
        </fn>
        <fn id="FN15">
          <label>15</label>
          <p>BC Cancer Agency, Vancouver, British Columbia V5Z 4S6, Canada.</p>
        </fn>
        <fn id="FN16">
          <label>16</label>
          <p>Mayo Clinic, Rochester, Minnesota 55905, USA.</p>
        </fn>
        <fn id="FN17">
          <label>17</label>
          <p>University of Southern California, Los Angeles, California 90033, USA.</p>
        </fn>
        <fn id="FN18">
          <label>18</label>
          <p>University of California Santa Cruz, Santa Cruz, California 95064, USA.</p>
        </fn>
        <fn id="FN19">
          <label>19</label>
          <p>Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.</p>
        </fn>
        <fn id="FN20">
          <label>20</label>
          <p>University of Kentucky, Lexington, Kentucky 40515, USA.</p>
        </fn>
        <fn id="FN21">
          <label>21</label>
          <p>Buck Institute for Age Research, Novato, California 94945, USA.</p>
        </fn>
        <fn id="FN22">
          <label>22</label>
          <p>Howard Hughes Medical Institute, University of California Santa Cruz, Santa Cruz, California 95064, USA.</p>
        </fn>
        <fn id="FN23">
          <label>23</label>
          <p>Oregon Health and Science University, Portland, Oregon 97239, USA.</p>
        </fn>
        <fn id="FN24">
          <label>24</label>
          <p>International Genomics Consortium, Phoenix, Arizona 85004, USA.</p>
        </fn>
        <fn id="FN25">
          <label>25</label>
          <p>Analytical Biological Services, Inc., Wilmington, Delaware 19801, USA.</p>
        </fn>
        <fn id="FN26">
          <label>26</label>
          <p>University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.</p>
        </fn>
        <fn id="FN27">
          <label>27</label>
          <p>Cleveland Clinic, Cleveland, Ohio 44195, USA.</p>
        </fn>
        <fn id="FN28">
          <label>28</label>
          <p>Christiana Care, Newark, Delaware 19713, USA.</p>
        </fn>
        <fn id="FN29">
          <label>29</label>
          <p>Cureline, Inc., South San Francisco, California 94080, USA.</p>
        </fn>
        <fn id="FN30">
          <label>30</label>
          <p>Emory University, Atlanta, Georgia 30322, USA.</p>
        </fn>
        <fn id="FN31">
          <label>31</label>
          <p>Fox Chase Cancer Center, Philadelphia, Philadelphia 19111, USA.</p>
        </fn>
        <fn id="FN32">
          <label>32</label>
          <p>ILSbio, Chestertown, Maryland 21620, USA.</p>
        </fn>
        <fn id="FN33">
          <label>33</label>
          <p>Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.</p>
        </fn>
        <fn id="FN34">
          <label>34</label>
          <p>Individumed, Silver Spring, Maryland 20910, USA.</p>
        </fn>
        <fn id="FN35">
          <label>35</label>
          <p>The Prince Charles Hospital and the University of Queensland Thoracic Research Center, Brisbane, 4032, Australia.</p>
        </fn>
        <fn id="FN36">
          <label>36</label>
          <p>Sullivan Nicolaides Pathology &amp; John Flynn Hospital, Tugun 4680, Australia.</p>
        </fn>
        <fn id="FN37">
          <label>37</label>
          <p>Lahey Hospital and Medical Center, Burlington, Massachusetts 01805, USA.</p>
        </fn>
        <fn id="FN38">
          <label>38</label>
          <p>NYU Langone Medical Center, New York, New York 10016, USA.</p>
        </fn>
        <fn id="FN39">
          <label>39</label>
          <p>Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada.</p>
        </fn>
        <fn id="FN40">
          <label>40</label>
          <p>Penrose St. Francis Health Services, Colorado Springs, Colorado 80907, USA.</p>
        </fn>
        <fn id="FN41">
          <label>41</label>
          <p>Roswell Park Cancer Center, Buffalo, New York 14263, USA.</p>
        </fn>
        <fn id="FN42">
          <label>42</label>
          <p>Rush University Medical Center, Chicago, Illinois 60612, USA.</p>
        </fn>
        <fn id="FN43">
          <label>43</label>
          <p>St. Petersburg Academic University, St Petersburg 199034, Russia.</p>
        </fn>
        <fn id="FN44">
          <label>44</label>
          <p>Thoraxklinik am Universitätsklinikum Heidelberg, 69126 Heidelberg, Germany.</p>
        </fn>
        <fn id="FN45">
          <label>45</label>
          <p>University Heidelberg, 69120 Heidelberg, Germany.</p>
        </fn>
        <fn id="FN46">
          <label>46</label>
          <p>University of Cologne, 50931 Cologne, Germany.</p>
        </fn>
        <fn id="FN47">
          <label>47</label>
          <p>University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida 33136, USA.</p>
        </fn>
        <fn id="FN48">
          <label>48</label>
          <p>University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.</p>
        </fn>
        <fn id="FN49">
          <label>49</label>
          <p>Center Hospitalier Universitaire Vaudois, Lausanne and European Thoracic Oncology Platform, CH-1011 Lausanne, Switzerland.</p>
        </fn>
        <fn id="FN50">
          <label>50</label>
          <p>Ziauddin University Hospital, Karachi, 75300, Pakistan.</p>
        </fn>
        <fn id="FN51">
          <label>51</label>
          <p>SRA International, Inc., Fairfax, Virginia 22033, USA.</p>
        </fn>
        <fn id="FN52">
          <label>52</label>
          <p>National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.</p>
        </fn>
        <fn id="FN53">
          <label>53</label>
          <p>National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.</p>
        </fn>
        <fn id="FN54">
          <p><xref rid="SD1" ref-type="supplementary-material">Supplementary Information</xref> is available in the online version of the paper.</p>
        </fn>
        <fn id="FN55" fn-type="con">
          <p><bold>Author Contributions</bold> The Cancer Genome Atlas Research Network contributed collectively to this study. Biospecimens were provided by the tissue source sites and processed by the biospecimen core resource. Data generation and analyses were performed by the genome sequencing centres, cancer genome characterization centres and genome data analysis centres. All data were released through the data coordinating centre. The National Cancer Institute and National Human Genome Research Institute project teams coordinated project activities. We also acknowledge the following TCGA investigators who made substantial contributions to the project: E. A. Collisson (manuscript coordinator); J. D. Campbell, J. Chmielecki, (analysis coordinators); C. Sougnez (data coordinator); J. D. Campbell, M. Rosenberg, W. Lee, J. Chmielecki, M. Ladanyi, and G. Getz (DNA sequence analysis); M. D. Wilkerson, A. N. Brooks, and D. N. Hayes (mRNA sequence analysis); L. Danilova and L. Cope (DNA methylation analysis); A. D. Cherniack (copy number analysis); M. D. Wilkerson and A. Hadjipanayis (translocations); N. Schultz, W. Lee, E. A. Collisson, A. H. Berger, J. Chmielecki, C. J. Creighton, L. A. Byers and M. Ladanyi (pathway analysis); A. Chu and A. G. Robertson (miRNA sequence analysis); W. Travis and D. A. Wigle (pathology and clinical expertise); L. A. Byers and G. B. Mills (reverse phase protein arrays); S. B. Baylin, R. Govindan and M. Meyerson (project chairs).</p>
        </fn>
        <fn id="FN56">
          <p><bold>Author Information</bold> The primary and processed data used to generate the analyses presented here can be downloaded by registered users from The Cancer Genome Atlas at (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp">https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp</ext-link>). All of the primary sequence files are deposited in cgHub and all other data are deposited at the Data Coordinating Center (DCC) for public access (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>), (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cghub.ucsc.edu/">https://cghub.ucsc.edu/</ext-link>) and (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/luad_2014/">https://tcga-data.nci.nih.gov/docs/publications/luad_2014/</ext-link>). Reprints and permissions information is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="www.nature.com/reprints">www.nature.com/reprints</ext-link>. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to M.M. (<email>matthew_meyerson@dfci.harvard.edu</email>).</p>
        </fn>
      </fn-group>
      <ref-list>
        <ref id="R1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Paez</surname>
                <given-names>JG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title><italic toggle="yes">EGFR</italic> mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title>
            <source>Science</source>
            <volume>304</volume>
            <fpage>1497</fpage>
            <lpage>1500</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15118125</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1099314</pub-id>
          </element-citation>
        </ref>
        <ref id="R2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kwak</surname>
                <given-names>EL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title>
            <source>N Engl J Med</source>
            <volume>363</volume>
            <fpage>1693</fpage>
            <lpage>1703</lpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20979469</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1006448</pub-id>
            <pub-id pub-id-type="pmcid">PMC3014291</pub-id>
          </element-citation>
        </ref>
        <ref id="R3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bergethon</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>ROS1 rearrangements define a unique molecular class of lung cancers</article-title>
            <source>J Clin Oncol</source>
            <volume>30</volume>
            <fpage>863</fpage>
            <lpage>870</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22215748</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.35.6345</pub-id>
            <pub-id pub-id-type="pmcid">PMC3295572</pub-id>
          </element-citation>
        </ref>
        <ref id="R4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Drilon</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas</article-title>
            <source>Cancer Discov</source>
            <volume>3</volume>
            <fpage>630</fpage>
            <lpage>635</lpage>
            <year>2013</year>
            <pub-id pub-id-type="pmid">23533264</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-13-0035</pub-id>
            <pub-id pub-id-type="pmcid">PMC4160032</pub-id>
          </element-citation>
        </ref>
        <ref id="R5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stephens</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Lung cancer: intragenic ERBB2 kinase mutations in tumours</article-title>
            <source>Nature</source>
            <volume>431</volume>
            <fpage>525</fpage>
            <lpage>526</lpage>
            <year>2004</year>
            <pub-id pub-id-type="pmid">15457249</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/431525b</pub-id>
          </element-citation>
        </ref>
        <ref id="R6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>p53: a frequent target for genetic abnormalities in lung cancer</article-title>
            <source>Science</source>
            <volume>246</volume>
            <fpage>491</fpage>
            <lpage>494</lpage>
            <year>1989</year>
            <pub-id pub-id-type="pmid">2554494</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.2554494</pub-id>
          </element-citation>
        </ref>
        <ref id="R7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Sanchez-Cespedes</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung</article-title>
            <source>Cancer Res</source>
            <volume>62</volume>
            <fpage>3659</fpage>
            <lpage>3662</lpage>
            <year>2002</year>
            <pub-id pub-id-type="pmid">12097271</pub-id>
          </element-citation>
        </ref>
        <ref id="R8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shapiro</surname>
                <given-names>GI</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Reciprocal Rb inactivation and p16<sup>INK4</sup> expression in primary lung cancers and cell lines</article-title>
            <source>Cancer Res</source>
            <volume>55</volume>
            <fpage>505</fpage>
            <lpage>509</lpage>
            <year>1995</year>
            <pub-id pub-id-type="pmid">7834618</pub-id>
          </element-citation>
        </ref>
        <ref id="R9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer</article-title>
            <source>PLoS Med</source>
            <volume>3</volume>
            <fpage>e420</fpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">17020408</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0030420</pub-id>
            <pub-id pub-id-type="pmcid">PMC1584412</pub-id>
          </element-citation>
        </ref>
        <ref id="R10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Medina</surname>
                <given-names>PP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Frequent <italic toggle="yes">BRG1/SMARCA4</italic>-inactivating mutations in human lung cancer cell lines</article-title>
            <source>Hum Mutat</source>
            <volume>29</volume>
            <fpage>617</fpage>
            <lpage>622</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18386774</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/humu.20730</pub-id>
          </element-citation>
        </ref>
        <ref id="R11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ding</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mutations affect key pathways in lung adenocarcinoma</article-title>
            <source>Nature</source>
            <volume>455</volume>
            <fpage>1069</fpage>
            <lpage>1075</lpage>
            <year>2008</year>
            <pub-id pub-id-type="pmid">18948947</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature07423</pub-id>
            <pub-id pub-id-type="pmcid">PMC2694412</pub-id>
          </element-citation>
        </ref>
        <ref id="R12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Imielinski</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing</article-title>
            <source>Cell</source>
            <volume>150</volume>
            <fpage>1107</fpage>
            <lpage>1120</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22980975</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.08.029</pub-id>
            <pub-id pub-id-type="pmcid">PMC3557932</pub-id>
          </element-citation>
        </ref>
        <ref id="R13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Govindan</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Genomic landscape of non-small cell lung cancer in smokers and never-smokers</article-title>
            <source>Cell</source>
            <volume>150</volume>
            <fpage>1121</fpage>
            <lpage>1134</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22980976</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.08.024</pub-id>
            <pub-id pub-id-type="pmcid">PMC3656590</pub-id>
          </element-citation>
        </ref>
        <ref id="R14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <name name-style="western">
                <surname>Brambilla</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Riely</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>New pathologic classification of lung cancer: relevance for clinical practice and clinical trials</article-title>
            <source>J Clin Oncol</source>
            <volume>31</volume>
            <fpage>992</fpage>
            <lpage>1001</lpage>
            <year>2013</year>
            <pub-id pub-id-type="pmid">23401443</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.46.9270</pub-id>
          </element-citation>
        </ref>
        <ref id="R15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>The Cancer Genome Atlas Research Network</collab>
            <article-title>Comprehensive genomic characterization of squamous cell lung cancers</article-title>
            <source>Nature</source>
            <volume>489</volume>
            <fpage>519</fpage>
            <lpage>525</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22960745</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11404</pub-id>
            <pub-id pub-id-type="pmcid">PMC3466113</pub-id>
          </element-citation>
        </ref>
        <ref id="R16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Carter</surname>
                <given-names>SL</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Absolute quantification of somatic DNA alterations in human cancer</article-title>
            <source>Nature Biotechnol</source>
            <volume>30</volume>
            <fpage>413</fpage>
            <lpage>421</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22544022</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2203</pub-id>
            <pub-id pub-id-type="pmcid">PMC4383288</pub-id>
          </element-citation>
        </ref>
        <ref id="R17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>
            <source>Nature Biotechnol</source>
            <volume>31</volume>
            <fpage>213</fpage>
            <lpage>219</lpage>
            <year>2013</year>
            <pub-id pub-id-type="pmid">23396013</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2514</pub-id>
            <pub-id pub-id-type="pmcid">PMC3833702</pub-id>
          </element-citation>
        </ref>
        <ref id="R18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lawrence</surname>
                <given-names>MS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Discovery and saturation analysis of cancer genes across 21 tumour types</article-title>
            <source>Nature</source>
            <volume>505</volume>
            <fpage>495</fpage>
            <lpage>501</lpage>
            <year>2014</year>
            <pub-id pub-id-type="pmid">24390350</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12912</pub-id>
            <pub-id pub-id-type="pmcid">PMC4048962</pub-id>
          </element-citation>
        </ref>
        <ref id="R19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hurlin</surname>
                <given-names>PJ</given-names>
              </name>
              <name name-style="western">
                <surname>Steingrimsson</surname>
                <given-names>E</given-names>
              </name>
              <name name-style="western">
                <surname>Copeland</surname>
                <given-names>NG</given-names>
              </name>
              <name name-style="western">
                <surname>Jenkins</surname>
                <given-names>NA</given-names>
              </name>
              <name name-style="western">
                <surname>Eisenman</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif</article-title>
            <source>EMBO J</source>
            <volume>18</volume>
            <fpage>7019</fpage>
            <lpage>7028</lpage>
            <year>1999</year>
            <pub-id pub-id-type="pmid">10601024</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/18.24.7019</pub-id>
            <pub-id pub-id-type="pmcid">PMC1171765</pub-id>
          </element-citation>
        </ref>
        <ref id="R20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Peifer</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer</article-title>
            <source>Nature Genet</source>
            <volume>44</volume>
            <fpage>1104</fpage>
            <lpage>1110</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22941188</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2396</pub-id>
            <pub-id pub-id-type="pmcid">PMC4915822</pub-id>
          </element-citation>
        </ref>
        <ref id="R21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Rudin</surname>
                <given-names>CM</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comprehensive genomic analysis identifies <italic toggle="yes">SOX2</italic> as a frequently amplified gene in small-cell lung cancer</article-title>
            <source>Nature Genet</source>
            <volume>44</volume>
            <fpage>1111</fpage>
            <lpage>1116</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22941189</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2405</pub-id>
            <pub-id pub-id-type="pmcid">PMC3557461</pub-id>
          </element-citation>
        </ref>
        <ref id="R22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Tokumo</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers</article-title>
            <source>Clin Cancer Res</source>
            <volume>11</volume>
            <fpage>1167</fpage>
            <lpage>1173</lpage>
            <year>2005</year>
            <pub-id pub-id-type="pmid">15709185</pub-id>
          </element-citation>
        </ref>
        <ref id="R23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Coleman</surname>
                <given-names>MP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A novel gene, DXS8237E, lies within 20 kb upstream of UBE1 in Xp11.23 and has a different X inactivation status</article-title>
            <source>Genomics</source>
            <volume>31</volume>
            <fpage>135</fpage>
            <lpage>138</lpage>
            <year>1996</year>
            <pub-id pub-id-type="pmid">8808293</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/geno.1996.0022</pub-id>
          </element-citation>
        </ref>
        <ref id="R24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Weir</surname>
                <given-names>BA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Characterizing the cancer genome in lung adenocarcinoma</article-title>
            <source>Nature</source>
            <volume>450</volume>
            <fpage>893</fpage>
            <lpage>898</lpage>
            <year>2007</year>
            <pub-id pub-id-type="pmid">17982442</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature06358</pub-id>
            <pub-id pub-id-type="pmcid">PMC2538683</pub-id>
          </element-citation>
        </ref>
        <ref id="R25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Stephens</surname>
                <given-names>PJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Massive genomic rearrangement acquired in a single catastrophic event during cancer development</article-title>
            <source>Cell</source>
            <volume>144</volume>
            <fpage>27</fpage>
            <lpage>40</lpage>
            <year>2011</year>
            <pub-id pub-id-type="pmid">21215367</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.11.055</pub-id>
            <pub-id pub-id-type="pmcid">PMC3065307</pub-id>
          </element-citation>
        </ref>
        <ref id="R26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kong-Beltran</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Somatic mutations lead to an oncogenic deletion of Met in lung cancer</article-title>
            <source>Cancer Res</source>
            <volume>66</volume>
            <fpage>283</fpage>
            <lpage>289</lpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">16397241</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-05-2749</pub-id>
          </element-citation>
        </ref>
        <ref id="R27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Seo</surname>
                <given-names>JS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The transcriptional landscape and mutational profile of lung adenocarcinoma</article-title>
            <source>Genome Res</source>
            <volume>22</volume>
            <fpage>2109</fpage>
            <lpage>2119</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22975805</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.145144.112</pub-id>
            <pub-id pub-id-type="pmcid">PMC3483540</pub-id>
          </element-citation>
        </ref>
        <ref id="R28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name name-style="western">
                <surname>Romfo</surname>
                <given-names>CM</given-names>
              </name>
              <name name-style="western">
                <surname>Nilsen</surname>
                <given-names>TW</given-names>
              </name>
              <name name-style="western">
                <surname>Green</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Functional recognition of the 3′ splice site AG by the splicing factor U2AF<sup>35</sup></article-title>
            <source>Nature</source>
            <volume>402</volume>
            <fpage>832</fpage>
            <lpage>835</lpage>
            <year>1999</year>
            <pub-id pub-id-type="pmid">10617206</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/45590</pub-id>
          </element-citation>
        </ref>
        <ref id="R29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Brooks</surname>
                <given-names>AN</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A pan-cancer analysis of transcriptome changes associated with somatic mutations in <italic toggle="yes">U2AF1</italic> reveals commonly altered splicing events</article-title>
            <source>PLoS ONE</source>
            <volume>9</volume>
            <fpage>e87361</fpage>
            <year>2014</year>
            <pub-id pub-id-type="pmid">24498085</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0087361</pub-id>
            <pub-id pub-id-type="pmcid">PMC3909098</pub-id>
          </element-citation>
        </ref>
        <ref id="R30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pao</surname>
                <given-names>W</given-names>
              </name>
              <name name-style="western">
                <surname>Hutchinson</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Chipping away at the lung cancer genome</article-title>
            <source>Nature Med</source>
            <volume>18</volume>
            <fpage>349</fpage>
            <lpage>351</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22395697</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.2697</pub-id>
          </element-citation>
        </ref>
        <ref id="R31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Beroukhim</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma</article-title>
            <source>Proc Natl Acad Sci USA</source>
            <volume>104</volume>
            <fpage>20007</fpage>
            <lpage>20012</lpage>
            <year>2007</year>
            <pub-id pub-id-type="pmid">18077431</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0710052104</pub-id>
            <pub-id pub-id-type="pmcid">PMC2148413</pub-id>
          </element-citation>
        </ref>
        <ref id="R32">
          <label>32</label>
          <element-citation publication-type="web">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Berger</surname>
                <given-names>AH</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Oncogenic <italic toggle="yes">RIT1</italic> mutations in lung adenocarcinoma</article-title>
            <source>Oncogene</source>
            <comment>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/onc.2013.581">http://dx.doi.org/10.1038/onc.2013.581</ext-link>
            </comment>
            <year>2014</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/onc.2013.581</pub-id>
            <pub-id pub-id-type="pmcid">PMC4150988</pub-id>
            <pub-id pub-id-type="pmid">24469055</pub-id>
          </element-citation>
        </ref>
        <ref id="R33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Creighton</surname>
                <given-names>CJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER<sup>+</sup> breast cancer</article-title>
            <source>Breast Cancer Res</source>
            <volume>12</volume>
            <fpage>R40</fpage>
            <year>2010</year>
            <pub-id pub-id-type="pmid">20569503</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/bcr2594</pub-id>
            <pub-id pub-id-type="pmcid">PMC2917035</pub-id>
          </element-citation>
        </ref>
        <ref id="R34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Wilkerson</surname>
                <given-names>MD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation</article-title>
            <source>PLoS ONE</source>
            <volume>7</volume>
            <fpage>e36530</fpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22590557</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0036530</pub-id>
            <pub-id pub-id-type="pmcid">PMC3349715</pub-id>
          </element-citation>
        </ref>
        <ref id="R35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Beer</surname>
                <given-names>DG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene-expression profiles predict survival of patients with lung adenocarcinoma</article-title>
            <source>Nature Med</source>
            <volume>8</volume>
            <fpage>816</fpage>
            <lpage>824</lpage>
            <year>2002</year>
            <pub-id pub-id-type="pmid">12118244</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm733</pub-id>
          </element-citation>
        </ref>
        <ref id="R36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Hayes</surname>
                <given-names>DN</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts</article-title>
            <source>J Clin Oncol</source>
            <volume>24</volume>
            <fpage>5079</fpage>
            <lpage>5090</lpage>
            <year>2006</year>
            <pub-id pub-id-type="pmid">17075127</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.05.1748</pub-id>
          </element-citation>
        </ref>
        <ref id="R37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bhattacharjee</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses</article-title>
            <source>Proc Natl Acad Sci USA</source>
            <volume>98</volume>
            <fpage>13790</fpage>
            <lpage>13795</lpage>
            <year>2001</year>
            <pub-id pub-id-type="pmid">11707567</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.191502998</pub-id>
            <pub-id pub-id-type="pmcid">PMC61120</pub-id>
          </element-citation>
        </ref>
        <ref id="R38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma</article-title>
            <source>J Thoracic Oncol</source>
            <volume>6</volume>
            <fpage>244</fpage>
            <lpage>285</lpage>
            <year>2011</year>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JTO.0b013e318206a221</pub-id>
            <pub-id pub-id-type="pmcid">PMC4513953</pub-id>
            <pub-id pub-id-type="pmid">21252716</pub-id>
          </element-citation>
        </ref>
        <ref id="R39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Yatabe</surname>
                <given-names>Y</given-names>
              </name>
              <name name-style="western">
                <surname>Mitsudomi</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Takahashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>TTF-1 expression in pulmonary adenocarcinomas</article-title>
            <source>Am J Surg Pathol</source>
            <volume>26</volume>
            <fpage>767</fpage>
            <lpage>773</lpage>
            <year>2002</year>
            <pub-id pub-id-type="pmid">12023581</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00000478-200206000-00010</pub-id>
          </element-citation>
        </ref>
        <ref id="R40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shinjo</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma</article-title>
            <source>Carcinogenesis</source>
            <volume>33</volume>
            <fpage>1277</fpage>
            <lpage>1285</lpage>
            <year>2012</year>
            <pub-id pub-id-type="pmid">22532250</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgs154</pub-id>
          </element-citation>
        </ref>
        <ref id="R41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mo</surname>
                <given-names>Q</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Pattern discovery and cancer gene identification in integrated cancer genomic data</article-title>
            <source>Proc Natl Acad Sci USA</source>
            <volume>110</volume>
            <fpage>4245</fpage>
            <lpage>4250</lpage>
            <year>2013</year>
            <pub-id pub-id-type="pmid">23431203</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1208949110</pub-id>
            <pub-id pub-id-type="pmcid">PMC3600490</pub-id>
          </element-citation>
        </ref>
        <ref id="R42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Lawrence</surname>
                <given-names>MS</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>
            <source>Nature</source>
            <volume>499</volume>
            <fpage>214</fpage>
            <lpage>218</lpage>
            <year>2013</year>
            <pub-id pub-id-type="pmid">23770567</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12213</pub-id>
            <pub-id pub-id-type="pmcid">PMC3919509</pub-id>
          </element-citation>
        </ref>
      </ref-list>
      <app-group>
        <app id="APP1">
          <title>The Cancer Genome Atlas Research Network</title>
          <p id="P23"><bold>Disease analysis working group</bold> Eric A. Collisson<sup><xref ref-type="fn" rid="FN1">1</xref></sup>, Joshua D. Campbell<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Angela N. Brooks<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN3">3</xref></sup>, Alice H. Berger<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, William Lee<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Juliann Chmielecki<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, David G. Beer<sup><xref ref-type="fn" rid="FN5">5</xref></sup>, Leslie Cope<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Chad J. Creighton<sup><xref ref-type="fn" rid="FN7">7</xref></sup>, Ludmila Danilova<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Li Ding<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Gad Getz<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN10">10</xref></sup>, Peter S. Hammerman<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, D. Neil Hayes<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Bryan Hernandez<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, James G. Herman<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, John V. Heymach<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Igor Jurisica<sup><xref ref-type="fn" rid="FN13">13</xref></sup>, Raju Kucherlapati<sup><xref ref-type="fn" rid="FN9">9</xref></sup>, David Kwiatkowski<sup><xref ref-type="fn" rid="FN14">14</xref></sup>, Marc Ladanyi<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Gordon Robertson<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Nikolaus Schultz<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Ronglai Shen<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Rileen Sinha<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Carrie Sougnez<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Ming-Sound Tsao<sup><xref ref-type="fn" rid="FN13">13</xref></sup>, William D. Travis<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, John N. Weinstein<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Dennis A. Wigle<sup><xref ref-type="fn" rid="FN16">16</xref></sup>, Matthew D. Wilkerson<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Andy Chu<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Andrew D. Cherniack<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Angela Hadjipanayis<sup><xref ref-type="fn" rid="FN9">9</xref></sup>, Mara Rosenberg<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Daniel J. Weisenberger<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Peter W. Laird<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Amie Radenbaugh<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Singer Ma<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Joshua M. Stuart<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Lauren Averett Byers<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Stephen B. Baylin<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Ramaswamy Govindan<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Matthew Meyerson<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN3">3</xref></sup></p>
          <p id="P24"><bold>Genome sequencing centres: The Eli &amp; Edythe L. Broad Institute</bold> Mara Rosenberg<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Stacey B. Gabriel<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Kristian Cibulskis<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Carrie Sougnez<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Jaegil Kim<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Chip Stewart<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Lee Lichtenstein<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Eric S. Lander<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN19">19</xref></sup>, Michael S. Lawrence<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Getz<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN10">10</xref></sup>; <bold>Washington University in St. Louis</bold> Cyriac Kandoth<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Robert Fulton<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Lucinda L. Fulton<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Michael D. McLellan<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Richard K. Wilson<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Kai Ye<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Catrina C. Fronick<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Christopher A. Maher<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Christopher A. Miller<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Michael C. Wendl<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Christopher Cabanski<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Li Ding<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Elaine Mardis<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Ramaswamy Govindan<sup><xref ref-type="fn" rid="FN8">8</xref></sup>; <bold>Baylor College of Medicine</bold> Chad J. Creighton<sup><xref ref-type="fn" rid="FN7">7</xref></sup>, David Wheeler<sup><xref ref-type="fn" rid="FN7">7</xref></sup></p>
          <p id="P25"><bold>Genome characterization centres: Canada’s Michael Smith Genome Sciences Centre, British Columbia Cancer Agency</bold> Miruna Balasundaram<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Yaron S. N. Butterfield<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Rebecca Carlsen<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Andy Chu<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Eric Chuah<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Noreen Dhalla<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Ranabir Guin<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Carrie Hirst<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Darlene Lee<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Haiyan I. Li<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Michael Mayo<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Richard A. Moore<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Andrew J. Mungall<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Jacqueline E. Schein<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Payal Sipahimalani<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Angela Tam<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Richard Varhol<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, A. Gordon Robertson<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Natasja Wye<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Nina Thiessen<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Robert A. Holt<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Steven J. M. Jones<sup><xref ref-type="fn" rid="FN15">15</xref></sup>, Marco A. Marra<sup><xref ref-type="fn" rid="FN15">15</xref></sup>; <bold>The Eli &amp; Edythe L. Broad Institute</bold> Joshua D. Campbell<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Angela N. Brooks<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN3">3</xref></sup>, Juliann Chmielecki<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Marcin Imielinski<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN10">10</xref></sup>, Robert C. Onofrio<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Eran Hodis<sup><xref ref-type="fn" rid="FN9">9</xref></sup>, Travis Zack<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Carrie Sougnez<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Elena Helman<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Chandra Sekhar Pedamallu<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Jill Mesirov<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Andrew D. Cherniack<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Gordon Saksena<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Steven E. Schumacher<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Scott L. Carter<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Bryan Hernandez<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Levi Garraway<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN3">3</xref>,<xref ref-type="fn" rid="FN9">9</xref></sup>, Rameen Beroukhim<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN3">3</xref>,<xref ref-type="fn" rid="FN9">9</xref></sup>, Stacey B. Gabriel<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Gad Getz<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN10">10</xref></sup>, Matthew Meyerson<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN3">3</xref>,<xref ref-type="fn" rid="FN9">9</xref></sup>; <bold>Harvard Medical School/Brigham &amp; Women’s Hospital/MD Anderson Cancer Center</bold> Angela Hadjipanayis<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>, Semin Lee<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>, Harshad S. Mahadeshwar<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Angeliki Pantazi<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>, Alexei Protopopov<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Xiaojia Ren<sup><xref ref-type="fn" rid="FN9">9</xref></sup>, Sahil Seth<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Xingzhi Song<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Jiabin Tang<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Lixing Yang<sup><xref ref-type="fn" rid="FN9">9</xref></sup>, JianhuaZhang<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Peng-Chieh Chen<sup><xref ref-type="fn" rid="FN9">9</xref></sup>, Michael Parfenov<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>, Andrew Wei Xu<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>, Netty Santoso<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>, Lynda Chin<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Peter J. Park<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup> &amp; Raju Kucherlapati<sup><xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN14">14</xref></sup>; <bold>University of North Carolina, Chapel Hill</bold> Katherine A. Hoadley<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, J. Todd Auman<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Shaowu Meng<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Yan Shi<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Elizabeth Buda<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Scot Waring<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Umadevi Veluvolu<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Donghui Tan<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Piotr A. Mieczkowski<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Corbin D. Jones<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Janae V. Simons<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Matthew G. Soloway<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Tom Bodenheimer<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Stuart R. Jefferys<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Jeffrey Roach<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Alan P. Hoyle<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Junyuan Wu<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Saianand Balu<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Darshan Singh<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Jan F. Prins<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, J.S. Marron<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Joel S. Parker<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, D. Neil Hayes<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Charles M. Perou<sup><xref ref-type="fn" rid="FN11">11</xref></sup>; <bold>University of Kentucky</bold> Jinze Liu<sup><xref ref-type="fn" rid="FN20">20</xref></sup>; <bold>The USC/JHU Epigenome Characterization Center</bold> Leslie Cope<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Ludmila Danilova<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Daniel J. Weisenberger<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Dennis T. Maglinte<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Philip H. Lai<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Moiz S. Bootwalla<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, David J. Van Den Berg<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Timothy Triche Jr<sup><xref ref-type="fn" rid="FN17">17</xref></sup>, Stephen B. Baylin<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Peter W. Laird<sup><xref ref-type="fn" rid="FN17">17</xref></sup></p>
          <p id="P26"><bold>Genome data analysis centres: The Eli &amp; Edythe L. Broad Institute</bold> Mara Rosenberg<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Lynda Chin<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Jianhua Zhang<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Juok Cho<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Daniel DiCara<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, David Heiman<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Pei Lin<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, William Mallard<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Douglas Voet<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Hailei Zhang<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Lihua Zou<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Michael S. Noble<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Michael S. Lawrence<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Gordon Saksena<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Nils Gehlenborg<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Helga Thorvaldsdottir<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Jill Mesirov<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Marc-Danie Nazaire<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Jim Robinson<sup><xref ref-type="fn" rid="FN2">2</xref></sup>, Gad Getz<sup><xref ref-type="fn" rid="FN2">2</xref>,<xref ref-type="fn" rid="FN9">9</xref>,<xref ref-type="fn" rid="FN10">10</xref></sup>; <bold>Memorial Sloan-Kettering Cancer Center</bold> William Lee<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, B. Arman Aksoy<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Giovanni Ciriello<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Barry S. Taylor<sup><xref ref-type="fn" rid="FN1">1</xref></sup>, Gideon Dresdner<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Jianjiong Gao<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Benjamin Gross<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Venkatraman E. Seshan<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Marc Ladanyi<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Boris Reva<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Rileen Sinha<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, S. Onur Sumer<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Nils Weinhold<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Nikolaus Schultz<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Ronglai Shen<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Chris Sander<sup><xref ref-type="fn" rid="FN4">4</xref></sup>; <bold>University of California, Santa Cruz/ Buck Institute</bold> Sam Ng<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Singer Ma<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Jingchun Zhu<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Amie Radenbaugh<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Joshua M. Stuart<sup><xref ref-type="fn" rid="FN18">18</xref></sup>, Christopher C. Benz<sup><xref ref-type="fn" rid="FN21">21</xref></sup>, Christina Yau<sup><xref ref-type="fn" rid="FN21">21</xref></sup> &amp; David Haussler<sup><xref ref-type="fn" rid="FN18">18</xref>,<xref ref-type="fn" rid="FN22">22</xref></sup>; <bold>Oregon Health &amp; Sciences University</bold> Paul T. Spellman<sup><xref ref-type="fn" rid="FN23">23</xref></sup>; <bold>University of North Carolina, Chapel Hill</bold> Matthew D. Wilkerson<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Joel S. Parker<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Katherine A. Hoadley<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Patrick K. Kimes<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, D. Neil Hayes<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Charles M. Perou<sup><xref ref-type="fn" rid="FN11">11</xref></sup>; <bold>The University of Texas MD Anderson Cancer Center</bold> Bradley M. Broom<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Jing Wang<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Yiling Lu<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Patrick Kwok Shing Ng<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Lixia Diao<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Lauren Averett Byers<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Wenbin Liu<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, John V. Heymach<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Christopher I. Amos<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, John N. Weinstein<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Rehan Akbani<sup><xref ref-type="fn" rid="FN12">12</xref></sup>, Gordon B. Mills<sup><xref ref-type="fn" rid="FN12">12</xref></sup></p>
          <p id="P27"><bold>Biospecimen core resource: International Genomics Consortium</bold> Erin Curley<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, Joseph Paulauskis<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, Kevin Lau<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, Scott Morris<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, Troy Shelton<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, David Mallery<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, Johanna Gardner<sup><xref ref-type="fn" rid="FN24">24</xref></sup>, Robert Penny<sup><xref ref-type="fn" rid="FN24">24</xref></sup></p>
          <p id="P28"><bold>Tissue source sites: Analytical Biological Service, Inc.</bold> Charles Saller<sup><xref ref-type="fn" rid="FN25">25</xref></sup>, Katherine Tarvin<sup><xref ref-type="fn" rid="FN25">25</xref></sup>; <bold>Brigham &amp; Women’s Hospital</bold> William G. Richards<sup><xref ref-type="fn" rid="FN14">14</xref></sup>; <bold>University of Alabama at Birmingham</bold> Robert Cerfolio<sup><xref ref-type="fn" rid="FN26">26</xref></sup>, Ayesha Bryant<sup><xref ref-type="fn" rid="FN26">26</xref></sup>; <bold>Cleveland Clinic:</bold> Daniel P. Raymond<sup><xref ref-type="fn" rid="FN27">27</xref></sup>, Nathan A. Pennell<sup><xref ref-type="fn" rid="FN27">27</xref></sup>, Carol Farver<sup><xref ref-type="fn" rid="FN27">27</xref></sup>; <bold>Christiana Care</bold> Christine Czerwinski<sup><xref ref-type="fn" rid="FN28">28</xref></sup>, Lori Huelsenbeck-Dill<sup><xref ref-type="fn" rid="FN28">28</xref></sup>, Mary Iacocca<sup><xref ref-type="fn" rid="FN28">28</xref></sup>, Nicholas Petrelli<sup><xref ref-type="fn" rid="FN28">28</xref></sup>, Brenda Rabeno<sup><xref ref-type="fn" rid="FN28">28</xref></sup>, Jennifer Brown<sup><xref ref-type="fn" rid="FN28">28</xref></sup>, Thomas Bauer<sup><xref ref-type="fn" rid="FN28">28</xref></sup>; <bold>Cureline</bold> Oleg Dolzhanskiy<sup><xref ref-type="fn" rid="FN29">29</xref></sup>, Olga Potapova<sup><xref ref-type="fn" rid="FN29">29</xref></sup>, Daniil Rotin<sup><xref ref-type="fn" rid="FN29">29</xref></sup>, Olga Voronina<sup><xref ref-type="fn" rid="FN29">29</xref></sup>, Elena Nemirovich-Danchenko<sup><xref ref-type="fn" rid="FN29">29</xref></sup>, Konstantin V. Fedosenko<sup><xref ref-type="fn" rid="FN29">29</xref></sup>; <bold>Emory University</bold> Anthony Gal<sup><xref ref-type="fn" rid="FN30">30</xref></sup>, Madhusmita Behera<sup><xref ref-type="fn" rid="FN30">30</xref></sup>, Suresh S. Ramalingam<sup><xref ref-type="fn" rid="FN30">30</xref></sup>, Gabriel Sica<sup><xref ref-type="fn" rid="FN30">30</xref></sup>; <bold>Fox Chase Cancer Center</bold> Douglas Flieder<sup><xref ref-type="fn" rid="FN31">31</xref></sup>, Jeff Boyd<sup><xref ref-type="fn" rid="FN31">31</xref></sup>, JoEllen Weaver<sup><xref ref-type="fn" rid="FN31">31</xref></sup>; ILSbio Bernard Kohl<sup><xref ref-type="fn" rid="FN32">32</xref></sup>, Dang Huy Quoc Thinh<sup><xref ref-type="fn" rid="FN32">32</xref></sup>; <bold>Indiana University</bold> George Sandusky<sup><xref ref-type="fn" rid="FN33">33</xref></sup>; <bold>Indivumed</bold> Hartmut Juhl<sup><xref ref-type="fn" rid="FN34">34</xref></sup>; <bold>John Flynn Hospital</bold> Edwina Duhig<sup><xref ref-type="fn" rid="FN35">35</xref>,<xref ref-type="fn" rid="FN36">36</xref></sup>; <bold>Johns Hopkins University</bold> Peter Illei<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Edward Gabrielson<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, James Shin<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Beverly Lee<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Kristen Rogers<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Dante Trusty<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Malcolm V. Brock<sup><xref ref-type="fn" rid="FN6">6</xref></sup>; <bold>Lahey Hospital &amp; Medical Center</bold> Christina Williamson<sup><xref ref-type="fn" rid="FN37">37</xref></sup>, Eric Burks<sup><xref ref-type="fn" rid="FN37">37</xref></sup>, Kimberly Rieger-Christ<sup><xref ref-type="fn" rid="FN37">37</xref></sup>, Antonia Holway<sup><xref ref-type="fn" rid="FN37">37</xref></sup>, Travis Sullivan<sup><xref ref-type="fn" rid="FN37">37</xref></sup>; <bold>Mayo Clinic</bold> Dennis A. Wigle<sup><xref ref-type="fn" rid="FN16">16</xref></sup>, Michael K. Asiedu<sup><xref ref-type="fn" rid="FN16">16</xref></sup>, Farhad Kosari<sup><xref ref-type="fn" rid="FN16">16</xref></sup>; <bold>Memorial Sloan-Kettering Cancer Center</bold> William D. Travis<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Natasha Rekhtman<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Maureen Zakowski<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Valerie W. Rusch<sup><xref ref-type="fn" rid="FN4">4</xref></sup>; <bold>NYU Langone Medical Center</bold> Paul Zippile<sup><xref ref-type="fn" rid="FN38">38</xref></sup>, James Suh<sup><xref ref-type="fn" rid="FN38">38</xref></sup>, Harvey Pass<sup><xref ref-type="fn" rid="FN38">38</xref></sup>, Chandra Goparaju<sup><xref ref-type="fn" rid="FN38">38</xref></sup>, Yvonne Owusu-Sarpong<sup><xref ref-type="fn" rid="FN38">38</xref></sup>; <bold>Ontario Tumour Bank</bold> John M. S. Bartlett<sup><xref ref-type="fn" rid="FN39">39</xref></sup>, Sugy Kodeeswaran<sup><xref ref-type="fn" rid="FN39">39</xref></sup>, Jeremy Parfitt<sup><xref ref-type="fn" rid="FN39">39</xref></sup>, Harmanjatinder Sekhon<sup><xref ref-type="fn" rid="FN39">39</xref></sup>, Monique Albert<sup><xref ref-type="fn" rid="FN39">39</xref></sup>; <bold>Penrose St. Francis Health Services</bold> John Eckman<sup><xref ref-type="fn" rid="FN40">40</xref></sup>, Jerome B. Myers<sup><xref ref-type="fn" rid="FN40">40</xref></sup>; <bold>Roswell Park Cancer Institute</bold> Richard Cheney<sup><xref ref-type="fn" rid="FN41">41</xref></sup>, Carl Morrison<sup><xref ref-type="fn" rid="FN41">41</xref></sup>, Carmelo Gaudioso<sup><xref ref-type="fn" rid="FN41">41</xref></sup>; <bold>Rush University Medical Center</bold> Jeffrey A. Borgia<sup><xref ref-type="fn" rid="FN42">42</xref></sup>, Philip Bonomi<sup><xref ref-type="fn" rid="FN42">42</xref></sup>, Mark Pool<sup><xref ref-type="fn" rid="FN42">42</xref></sup>, Michael J. Liptay<sup><xref ref-type="fn" rid="FN42">42</xref></sup>; <bold>St. Petersburg Academic University</bold> Fedor Moiseenko<sup><xref ref-type="fn" rid="FN43">43</xref></sup>, Irina Zaytseva<sup><xref ref-type="fn" rid="FN43">43</xref></sup>; <bold>Thoraxklinik am Universitätsklinikum Heidelberg, Member of Biomaterial Bank Heidelberg (BMBH) &amp; Biobank Platform of the German Centre for Lung Research (DZL)</bold> Hendrik Dienemann<sup><xref ref-type="fn" rid="FN44">44</xref></sup>, Michael Meister<sup><xref ref-type="fn" rid="FN44">44</xref></sup>, Philipp A. Schnabel<sup><xref ref-type="fn" rid="FN45">45</xref></sup>, Thomas R. Muley<sup><xref ref-type="fn" rid="FN44">44</xref></sup>; <bold>University of Cologne</bold> Martin Peifer<sup><xref ref-type="fn" rid="FN46">46</xref></sup>; <bold>University of Miami</bold> Carmen Gomez-Fernandez<sup><xref ref-type="fn" rid="FN47">47</xref></sup>, Lynn Herbert<sup><xref ref-type="fn" rid="FN47">47</xref></sup>, Sophie Egea<sup><xref ref-type="fn" rid="FN47">47</xref></sup>; <bold>University of North Carolina</bold> Mei Huang<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Leigh B. Thorne<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Lori Boice<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Ashley Hill Salazar<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, William K. Funkhouser<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, W. Kimryn Rathmell<sup><xref ref-type="fn" rid="FN11">11</xref></sup>; <bold>University of Pittsburgh</bold> Rajiv Dhir<sup><xref ref-type="fn" rid="FN48">48</xref></sup>, Samuel A. Yousem<sup><xref ref-type="fn" rid="FN48">48</xref></sup>, Sanja Dacic<sup><xref ref-type="fn" rid="FN48">48</xref></sup>, Frank Schneider<sup><xref ref-type="fn" rid="FN48">48</xref></sup>, Jill M. Siegfried<sup><xref ref-type="fn" rid="FN48">48</xref></sup>; <bold>The University of Texas MD Anderson Cancer Center</bold> Richard Hajek<sup><xref ref-type="fn" rid="FN12">12</xref></sup>; <bold>Washington University School of Medicine</bold> Mark A. Watson<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Sandra McDonald<sup><xref ref-type="fn" rid="FN8">8</xref></sup>, Bryan Meyers<sup><xref ref-type="fn" rid="FN8">8</xref></sup>; <bold>Queensland Thoracic Research Center</bold> Belinda Clarke<sup><xref ref-type="fn" rid="FN35">35</xref></sup>, Ian A. Yang<sup><xref ref-type="fn" rid="FN35">35</xref></sup>, Kwun M. Fong<sup><xref ref-type="fn" rid="FN35">35</xref></sup>, Lindy Hunter<sup><xref ref-type="fn" rid="FN35">35</xref></sup>, Morgan Windsor<sup><xref ref-type="fn" rid="FN35">35</xref></sup>, Rayleen V. Bowman<sup><xref ref-type="fn" rid="FN35">35</xref></sup>; <bold>Center Hospitalier Universitaire Vaudois</bold> Solange Peters<sup><xref ref-type="fn" rid="FN49">49</xref></sup>, Igor Letovanec<sup><xref ref-type="fn" rid="FN49">49</xref></sup>; <bold>Ziauddin University Hospital</bold> Khurram Z. Khan<sup><xref ref-type="fn" rid="FN50">50</xref></sup></p>
          <p id="P29"><bold>Data Coordination Centre</bold> Mark A. Jensen<sup><xref ref-type="fn" rid="FN51">51</xref></sup>, Eric E. Snyder<sup><xref ref-type="fn" rid="FN51">51</xref></sup>, Deepak Srinivasan<sup><xref ref-type="fn" rid="FN51">51</xref></sup>, Ari B. Kahn<sup><xref ref-type="fn" rid="FN51">51</xref></sup>, Julien Baboud<sup><xref ref-type="fn" rid="FN51">51</xref></sup>, David A. Pot<sup><xref ref-type="fn" rid="FN51">51</xref></sup></p>
          <p id="P30"><bold>Project team: National Cancer Institute</bold> Kenna R. Mills Shaw<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, Margi Sheth<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, Tanja Davidsen<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, John A. Demchok<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, Liming Yang<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, Zhining Wang<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, Roy Tarnuzzer<sup><xref ref-type="fn" rid="FN52">52</xref></sup>, Jean Claude Zenklusen<sup><xref ref-type="fn" rid="FN52">52</xref></sup>; <bold>National Human Genome Research Institute</bold> Bradley A. Ozenberger<sup><xref ref-type="fn" rid="FN53">53</xref></sup>, Heidi J. Sofia<sup><xref ref-type="fn" rid="FN53">53</xref></sup></p>
          <p id="P31"><bold>Expert pathology panel</bold> William D. Travis<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Richard Cheney<sup><xref ref-type="fn" rid="FN41">41</xref></sup>, Belinda Clarke<sup><xref ref-type="fn" rid="FN35">35</xref></sup>, Sanja Dacic<sup><xref ref-type="fn" rid="FN48">48</xref></sup>, Edwina Duhig<sup><xref ref-type="fn" rid="FN36">36</xref>,<xref ref-type="fn" rid="FN35">35</xref></sup>, William K. Funkhouser<sup><xref ref-type="fn" rid="FN11">11</xref></sup>, Peter Illei<sup><xref ref-type="fn" rid="FN6">6</xref></sup>, Carol Farver<sup><xref ref-type="fn" rid="FN27">27</xref></sup>, Natasha Rekhtman<sup><xref ref-type="fn" rid="FN4">4</xref></sup>, Gabriel Sica<sup><xref ref-type="fn" rid="FN30">30</xref></sup>, James Suh<sup><xref ref-type="fn" rid="FN38">38</xref></sup> &amp; Ming-Sound Tsao<sup><xref ref-type="fn" rid="FN13">13</xref></sup></p>
        </app>
      </app-group>
    </back>
    <floats-group>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <title>Somatic mutations in lung adenocarcinoma</title>
          <p><bold>a,</bold> Co-mutation plot from whole exome sequencing of 230 lung adenocarcinomas. Data from TCGA samples were combined with previously published data<sup><xref rid="R12" ref-type="bibr">12</xref></sup> for statistical analysis. Co-mutation plot for all samples used in the statistical analysis (<italic toggle="yes">n</italic> =412) can be found in <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>. Significant genes with a corrected <italic toggle="yes">P</italic> value less than 0.025 were identified using the MutSig2CV algorithm and are ranked in order of decreasing prevalence. <bold>b</bold>, <bold>c</bold>, The differential patterns of mutation between samples classified as transversion high and transversion low samples (<bold>b</bold>) or male and female patients (<bold>c</bold>) are shown for all samples used in the statistical analysis (<italic toggle="yes">n</italic> =412). Stars indicate statistical significance using the Fisher’s exact test (black stars: <italic toggle="yes">q</italic> &lt;0.05, grey stars: <italic toggle="yes">P</italic> &lt;0.05) and are adjacent to the sample set with the higher percentage of mutated samples.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms629713f1.jpg"/>
      </fig>
      <fig id="F2" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <title>Aberrant RNA transcripts in lung adenocarcinoma associated with somatic DNA translocation or mutation</title>
          <p><bold>a,</bold> Normalized exon level RNA expression across fusion gene partners. Grey boxes around genes mark the regions that are removed as a consequence of the fusion. Junction points of the fusion events are also listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 9</xref>. Exon numbers refer to reference transcripts listed in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 9</xref>. <bold>b,</bold>
<italic toggle="yes">MET</italic> exon 14 skipping observed in the presence of exon 14 splice site mutation (ss mut), splice site deletion (ss del) or a Y1003* mutation. A total of 22 samples had insufficient coverage around exon 14 for quantification. The percentage skipping is (total expression minus exon 14 expression)/total expression. <bold>c,</bold> Significant differences in the frequency of 129 alternative splicing events in mRNA from tumours with <italic toggle="yes">U2AF1</italic> S34F tumours compared to <italic toggle="yes">U2AF1</italic> WT tumours (<italic toggle="yes">q</italic> value &lt;0.05). Consistent with the function of U2AF1 in 3′ splice site recognition, most splicing differences involved cassette exon and alternative 3′ splice site events (chi-squared test, <italic toggle="yes">P</italic> &lt;0.001).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms629713f2.jpg"/>
      </fig>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Identification of novel candidate driver genes</title>
          <p><bold>a,</bold> GISTIC analysis of focal amplifications in oncogene-negative (<italic toggle="yes">n</italic> =87) and oncogene-positive (<italic toggle="yes">n</italic> =143) TCGA samples identifies focal gains of <italic toggle="yes">MET</italic> and <italic toggle="yes">ERBB2</italic> that are specific to the oncogene-negative set (purple). <bold>b,</bold>
<italic toggle="yes">TP53, KEAP1, NF1</italic> and <italic toggle="yes">RIT1</italic> mutations are significantly enriched in samples otherwise lacking oncogene mutations (adjusted <italic toggle="yes">P</italic> &lt;0.05 by Fisher’s exact test). <bold>c,</bold> Co-mutation plot of variants of known significance within the RTK/RAS/RAF pathway in lung adenocarcinoma. Not shown are the 63 tumours lacking an identifiable driver lesion. Only canonical driver events, as defined in <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 9</xref>, and proposed driver events, are shown; hence not every alteration found is displayed. <bold>d,</bold> New candidate driver oncogenes (blue: 13% of cases) and known somatically activated drivers events (red: 63%) that activate the RTK/RAS/RAF pathway can be found in the majority of the 230 lung adenocarcinomas.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms629713f3.jpg"/>
      </fig>
      <fig id="F4" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <title>Pathway alterations in lung adenocarcinoma</title>
          <p><bold>a,</bold> Somatic alterations involving key pathway components for RTK signalling, mTOR signalling, oxidative stress response, proliferation and cell cycle progression, nucleosome remodelling, histone methylation, and RNA splicing/processing. <bold>b</bold>, <bold>c,</bold> Proteomic analysis by RPPA (<italic toggle="yes">n</italic> =181) <italic toggle="yes">P</italic> values by two-sided <italic toggle="yes">t</italic>-test. Box plots represent 5%, 25%, 75%, median, and 95%. PP, proximal proliferative; TRU, terminal respiratory unit; PI, proximal inflammatory. <bold>c,</bold> mTOR signalling may be activated, by either Akt (for example, via PI(3)K) or inactivation of AMPK (for example, via <italic toggle="yes">STK11</italic> loss). Tumours were separated into three main groups: those with PI(3)K-AKT activation, through either <italic toggle="yes">PIK3CA</italic> activating mutation or unknown mechanism (high p-AKT); those with LKB1-AMPK inactivation, through either <italic toggle="yes">STK11</italic> mutation or unknown mechanism with low levels of LKB1 and p-AMPK; and those showing none of the above features.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms629713f4.jpg"/>
      </fig>
      <fig id="F5" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <title>Integrative analysis</title>
          <p><bold>a</bold>–<bold>c</bold>, Integrating unsupervised analyses of 230 lung adenocarcinomas reveals significant interactions between molecular subtypes. Tumours are displayed as columns, grouped by mRNA expression subtypes (<bold>a</bold>), DNA methylation subtypes (<bold>b</bold>), and integrated subtypes by iCluster analysis (<bold>c</bold>). All displayed features are significantly associated with subtypes depicted. The CIMP phenotype is defined by the most variable CpG island and promoter probes.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms629713f5.jpg"/>
      </fig>
    </floats-group>
  </article>
</pmc-articleset>
